Since most basal-like tumors express EGFR, it seemed of interest to investigate the mutational status of KRAS in such tumors to provide scientific evidence for the evaluation of anti-EGFR therapies in the management of triple-negative breast cancer. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.